Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Medications and Techniques

Clin Gastroenterol Hepatol. 2016 Nov;14(11):1521-1532.e3. doi: 10.1016/j.cgh.2016.05.026. Epub 2016 May 27.

Abstract

Over the past 2 decades, it increasingly has been recognized that endoscopic retrograde cholangiopancreatography (ERCP) is the most predictable provocateur of acute pancreatitis, with an incidence of more than 15% in high-risk patients. For this reason, there has been considerable interest in the effect of periprocedural drug administration as well as different ERCP techniques on both the incidence and severity of post-ERCP pancreatitis. Although many agents and techniques have shown promise in small clinical studies, the majority of these have failed to yield consistent benefit in larger randomized patient groups. This review summarizes the data on medications and ERCP techniques that have been studied for the prevention of post-ERCP pancreatitis.

Keywords: ERCP; Medications; Pancreatitis; Prevention; Stents.

Publication types

  • Review

MeSH terms

  • Cholangiopancreatography, Endoscopic Retrograde / adverse effects*
  • Cholangiopancreatography, Endoscopic Retrograde / methods*
  • Humans
  • Pancreatitis / prevention & control*
  • Perioperative Care / methods*